ClinicalTrials.gg
CompletedNCT00332696Updated Sep 23, 2011Results posted

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

A Phase 2 interventional study of Octreotide LAR and Octreotide (Immediate release) in Peritoneal Neoplasms, Intestinal Obstruction and Carcinomatosis, sponsored by Novartis Pharmaceuticals. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Peritoneal Neoplasms with a site in France — 8 open to participants now, 9 under way, 2 of them phase 3. Peritoneal Neoplasms · France.

Enrollment
18th of 32
64 · median 73
Started
2005
with 1 other
Phase 2
7 of 40
1 open now
Registered
3rd of 40
by date
Lead sponsor
2 of 40
Novartis Pharmaceuticals

Among the 40 studies in Peritoneal Neoplasms with a site in France, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2005, is one of 7 in phase 2, and was the 3rd registered.

Peritoneal Neoplasms

249 studies on the registry are indexed under Peritoneal Neoplasms; 55 are open to participants now.

Browse Peritoneal Neoplasms studies →

Open to participants now

8 of the 40 studies in Peritoneal Neoplasms with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 49 Peritoneal Neoplasms studies recruiting now, 35 (71%) set no upper age limit and 8 (16%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Peritoneal Neoplasms with a site in France, or all of them as a file.
02

Study summary

To evaluate in combination with corticosteroid and local standard medical care the efficacy and safety of long-acting octreotide compared to placebo for the treatment of symptoms of inoperable bowel obstruction in patients with peritoneal carcinomatosis

03

Conditions studied

  • Peritoneal Neoplasms
  • Intestinal Obstruction
  • Carcinomatosis

Keywords

  • bowel obstruction,
  • peritoneal carcinomatosis
  • Octreotide
  • inoperable
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with symptoms and signs of inoperable bowel obstruction confirmed by a surgeon or clinic and radiographic assessment (CT scan or at least abdominal X-ray);
  • Confirmed peritoneal carcinomatosis (with one of the following criteria : surgery, imaging and/or cytology);
  • No corticotherapy at dose more than 1mg/kg equivalent-methylprednisolone, in the previous 2 weeks ;
  • No chemotherapy in the previous week;
  • No radio or chemotherapy planned at the inclusion and within the two weeks following inclusion
  • Authorized concomitant treatments for local standard medical care : antiemetics, antispasmodics, anti-Histamine2 (H2) drugs blockers or proton pump inhibitor, analgesics; nasogastric tube

Exclusion criteria

Exclusion Criteria:

  • Abnormal coagulation ( \< 60%, \< 50x10\^9/L).
  • Non authorized concomitant treatments :

    1. Anticholinergics such as scopolamine
    2. Other somatostatin analogues

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Octreotide

    Participants received Octreotide long-acting release (LAR) 30 mg intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received immediate-release Octreotide 600 µg/day (administered subcutaneously 2 or 3 times a day or via continuous intravenous (IV) or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.

    Drug: Octreotide LAR · Drug: Octreotide (Immediate release) · Drug: methylprednisolone

  • Placebo comparator
    Placebo

    Participants received physiologic saline solution intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received physiologic saline solution (administered subcutaneously 2 or 3 times a day or via continuous intravenous or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.

    Drug: methylprednisolone · Drug: Placebo

Interventions

  • Octreotide long-acting release (LAR) 30 mg intramuscular injection.

    Also known as: Sandostatin® LAR

  • Immediate-release Octreotide supplied in 100 µg/mL ampules.

    Also known as: Sandostatin®

  • methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).

  • DrugPlacebo

    Physiologic saline solution

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Success From Day 10 to Day 13

    Treatment Success was defined as: less than 2 episodes of vomiting on average per day for the 4 days prior to Day 14 \[from Day 10 to Day 13\] and no use of an Nasogastric Tube (NGT) since at least Day 10 and no use of an anticholinergic agent until Day 14. Treatment Failure is defined as: 2 or more episodes of vomiting per day on average for the 4 days prior to Day 14 or use of an NGT after Day 9 or use of an anticholinergic agent before Day 14 or withdrawal from the trial between Day 1 and Day 14 (included), whatever the cause.

    Time frame: Day 10 to Day 13

Secondary outcomes

  1. Number of Participants With Treatment Success From Day 5 to Day 7

    Day 7 treatment success was defined as improvement of symptoms in the previous 2 days (average number of vomiting episodes less than 2 from Day 5, no Nasogastric Tube (NGT) since Day 5 and no anticholinergic agent or withdrawal from trial).

    Time frame: Day 5 to Day 7

  2. Number of Vomiting Episodes Per Day at Day1, Day 2 and Day 14

    The mean number of vomiting episodes per a 24 hour period is presented for Day 1, Day 7 and Day 14.

    Time frame: Day 1, Day 7 and Day 14

  3. Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 1

    Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 1.

    Time frame: Day 1

  4. Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 7

    Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 7.

    Time frame: Day 7

  5. Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 14

    Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 14.

    Time frame: Day 14

  6. Number of Participants With Relief From Obstruction at Day 7 and Day 14

    Relief from obstruction is defined by combining restart of stools for at least the previous 3 days, less than 2 episodes of vomiting on average for the previous 4 days and the restarting of flatus (gas generated in the stomach or bowels) for at least the previous 12 hours.

    Time frame: Day 7 and Day 14

  7. Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 1

    Recurrence of bowel obstruction was confirmed by abdominal X-ray.

    Time frame: 1 Month

  8. Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 2

    Recurrence of bowel obstruction was confirmed by abdominal X-ray.

    Time frame: Month 2

  9. Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 3

    Recurrence of bowel obstruction was confirmed by abdominal X-ray.

    Time frame: Month 3

  10. Participant's Quality of Life Using the Edmonton Scale

    The Edmonton Scale consisted of 9 items: pain, activity, nausea, depression, anxiety, fatigue, appetite, sensation of well-being and dyspnea (difficult or labored breathing). Participants rated these items on a scale of 0 to 10, with 10 being the worse.

    Time frame: Day 1, Day 7, Day 14, Month 1, Month 2 and Month 3

07

Results

Posted Jun 15, 2011
Limitations and caveats
Study was terminated prematurely due to low enrollment

Participant flow

Participant flow — Overall Study
MilestoneOctreotidePlacebo
Started3232
Completed day 14 visit2115
Completed22
Not completed3030
Withdrew: Death2414
Withdrew: Insufficient therapeutic effect411
Withdrew: Adverse event12
Withdrew: Condition does not justify treatment02
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryNumber of Participants With Treatment Success From Day 10 to Day 13

Treatment Success was defined as: less than 2 episodes of vomiting on average per day for the 4 days prior to Day 14 \[from Day 10 to Day 13\] and no use of an Nasogastric Tube (NGT) since at least Day 10 and no use of an anticholinergic agent until Day 14. Treatment Failure is defined as: 2 or more episodes of vomiting per day on average for the 4 days prior to Day 14 or use of an NGT after Day 9 or use of an anticholinergic agent before Day 14 or withdrawal from the trial between Day 1 and Day 14 (included), whatever the cause.

Time frame:
Day 10 to Day 13
Reported as:
Number · Participants
Number of Participants With Treatment Success From Day 10 to Day 13
ParticipantsOctreotidePlacebo
TREATMENT SUCCESS129
Vomiting episodes <2 (per day)1913
Vomiting episodes ≥2 (per day)22
No Nasogastric Tube since Day 101413
Nasogastric Tube used since Day 1072
No Anticholinergic agents1811
Anticholinergic agents taken34
Premature discontinuation/missing data, failure1117
SecondaryNumber of Participants With Treatment Success From Day 5 to Day 7

Day 7 treatment success was defined as improvement of symptoms in the previous 2 days (average number of vomiting episodes less than 2 from Day 5, no Nasogastric Tube (NGT) since Day 5 and no anticholinergic agent or withdrawal from trial).

Time frame:
Day 5 to Day 7
Reported as:
Number · Participants
Number of Participants With Treatment Success From Day 5 to Day 7
ParticipantsOctreotidePlacebo
TREATMENT SUCCESS2220
Vomiting episodes <2 (per day) since Day 52825
Vomiting episodes ≥2 (per day) since Day 512
No Nasogastric Tube since Day 52224
Nasogastric Tube used since Day 573
No Anticholinergic agents2625
Anticholinergic agents taken32
Premature discontinuation/missing data35
SecondaryNumber of Vomiting Episodes Per Day at Day1, Day 2 and Day 14

The mean number of vomiting episodes per a 24 hour period is presented for Day 1, Day 7 and Day 14.

Time frame:
Day 1, Day 7 and Day 14
Reported as:
Mean · Vomiting episodes
Number of Vomiting Episodes Per Day at Day1, Day 2 and Day 14
Vomiting episodesOctreotidePlacebo
Day 11.2 ± 2.140.6 ± 1.85
Day 7 (n=31,31)0.3 ± 0.640.4 ± 0.84
Day 14 (n=28,27)0.3 ± 0.810.5 ± 2.12
SecondaryNumber of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 1

Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 1.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 1
ParticipantsOctreotidePlacebo
Score=01613
Score=112
Score=279
Score=388
SecondaryNumber of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 7

Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 7.

Time frame:
Day 7
Reported as:
Number · Participants
Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 7
ParticipantsOctreotidePlacebo
Score=02115
Score=129
Score=256
Score=331
SecondaryNumber of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 14

Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 14.

Time frame:
Day 14
Reported as:
Number · Participants
Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 14
ParticipantsOctreotidePlacebo
Score=02222
Score=123
Score=221
Score=321
SecondaryNumber of Participants With Relief From Obstruction at Day 7 and Day 14

Relief from obstruction is defined by combining restart of stools for at least the previous 3 days, less than 2 episodes of vomiting on average for the previous 4 days and the restarting of flatus (gas generated in the stomach or bowels) for at least the previous 12 hours.

Time frame:
Day 7 and Day 14
Reported as:
Number · Participants
Number of Participants With Relief From Obstruction at Day 7 and Day 14
ParticipantsOctreotidePlacebo
Relief from Obstruction: Day 7915
No Relief from Obstruction: Day 72012
Relief from Obstruction: Day 141110
No Relief from Obstruction: Day 14105
SecondaryNumber of Participants With Recurrence of an Episode of Bowel Obstruction at Month 1

Recurrence of bowel obstruction was confirmed by abdominal X-ray.

Time frame:
1 Month
Reported as:
Number · Participants
Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 1
ParticipantsOctreotidePlacebo
Recurrence at Month 112
No Recurrence at Month 11313
SecondaryNumber of Participants With Recurrence of an Episode of Bowel Obstruction at Month 2

Recurrence of bowel obstruction was confirmed by abdominal X-ray.

Time frame:
Month 2
Reported as:
Number · Participants
Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 2
ParticipantsOctreotidePlacebo
Recurrence at Month 222
No Recurrence at Month 265
SecondaryNumber of Participants With Recurrence of an Episode of Bowel Obstruction at Month 3

Recurrence of bowel obstruction was confirmed by abdominal X-ray.

Time frame:
Month 3
Reported as:
Number · Participants
Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 3
ParticipantsOctreotidePlacebo
Recurrence at Month 300
No Recurrence at Month 332
SecondaryParticipant's Quality of Life Using the Edmonton Scale

The Edmonton Scale consisted of 9 items: pain, activity, nausea, depression, anxiety, fatigue, appetite, sensation of well-being and dyspnea (difficult or labored breathing). Participants rated these items on a scale of 0 to 10, with 10 being the worse.

Time frame:
Day 1, Day 7, Day 14, Month 1, Month 2 and Month 3
Reported as:
Mean · Scores on a scale
Participant's Quality of Life Using the Edmonton Scale
Scores on a scaleOctreotidePlacebo
Day 1 (n=30,29)4.12 ± 1.1744.12 ± 1.360
Day 7 (n=24,26)4.23 ± 1.6953.37 ± 1.247
Day 14 (n=20,14)4.30 ± 1.6523.85 ± 1.860
Month 1 (n=11,13)4.18 ± 1.9054.49 ± 1.820
Month 2 (n=7,4)3.46 ± 2.3393.23 ± 1.609
Month 3 (n=2,2)0.05 ± 0.0711.60 ± 0.283

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Octreotide—6/32 (18.8%)24/32 (75%)
Placebo—6/32 (18.8%)19/32 (59.4%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventOctreotidePlacebo
General physical health deteriorationGeneral disorders1/323/32
SepsisInfections and infestations1/322/32
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders0/322/32
DyspnoeaRespiratory, thoracic and mediastinal disorders0/322/32
Cardiac arrestCardiac disorders1/320/32
Abdominal painGastrointestinal disorders0/321/32
AscitesGastrointestinal disorders1/320/32
Intestinal obstructionGastrointestinal disorders0/321/32
VomitingGastrointestinal disorders0/321/32
Disease progressionGeneral disorders0/321/32
Most frequent other events
Showing 10 of 45
Most frequent other events
EventOctreotidePlacebo
Abdominal painGastrointestinal disorders7/324/32
NauseaGastrointestinal disorders7/322/32
AstheniaGeneral disorders7/323/32
Disease progressionGeneral disorders7/322/32
VomitingGastrointestinal disorders6/325/32
DiarrhoeaGastrointestinal disorders5/323/32
DyspnoeaRespiratory, thoracic and mediastinal disorders5/323/32
HyponatraemiaMetabolism and nutrition disorders4/320/32
AnxietyPsychiatric disorders3/324/32
Confusional statePsychiatric disorders4/322/32

Baseline characteristics

Age Continuous
Age Continuous(years)OctreotidePlaceboTotal
Mean65.3 ± 9.5763.1 ± 12.3664.2 ± 11.02
Sex: Female, Male
Sex: Female, Male(Participants)OctreotidePlaceboTotal
Female252146
Male71118
08

Study locations

1 site
  • Novartis Investigative Site
    Creteil, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2006
First posted
Jun 2, 2006
Start
Sep 2005
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Jun 15, 2011
Last update
Sep 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00332696
Responsible party
Sponsor
First posted
Jun 2, 2006
Start date
Sep 2005
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Jun 15, 2011
Last update
Sep 23, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion